PTO/SB/08a (05-07)
Approved for use through 09/30/2007 OMB 0851-0031
U.S. Patent and Trademark Office, U.S. GEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are requ

U.S.PATENTS

	Ī
INFORMATION DISCLOSURE	Ī
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	ļ
(Not for Submission and of St 11 130)	Ī

Application Number		10787062		
Filing Date		2004-02-25		
First Named Inventor Kazu		non YASUDA et al.		
Art Unit		3738		
Examiner Name Miller		, Cheryl		
Attorney Docket Number		81880.0115		

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Pa of cited Doc	tentee or Applicant ument	Releva		Lines where ges or Relev		
	1	4888021	A	1989-12-19	Forte et al.			Corresponds to WO published application number 8908947 and Japanese published application number 3502291			
	2	5219362	A	1993-06-15	Tuke et al.						
If you wisi	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add		_	
			U.S.P	ATENT APPLI	CATION PUE	LICATIONS		Remove		=	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Name of Patentee or Applica of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wisl	h to a	dd additional U.S. Pub	lished Ap	plication citation	n information	please click the Ad	d button	Add		_	
				FOREIGN PA	TENT DOCU	MENTS		Remove			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	TA	
	1	3502291	JP	т	1991-05-30	Forte et al.		Correspond patent num and WO pu application	ber 4888021 blished number	×	
	2	8906947	wo	A1	1989-08-10	Joint Medical Produ Corp	ucts		is to US ber 4888021 se published		

If you wish	to a	dd add	itional Foreign Patent Document citation information ple	ase click the Add buttor	n Add	
			NON-PATENT LITERATURE DOC	UMENTS	Remove	
Examiner Initials*	Cite No	(bool	de name of the author (in CAPITAL LETTERS), title of to c, magazine, journal, serial, symposium, catalog, etc), di sher, city and/or country where published.			Ţ5
	1	Japai 2003	nese language office action and its English translation for corre 047009 lists the references above	sponding Japanese applic	cation number	×
If you wish	n to a	dd add	itional non-patent literature document citation information	n please click the Add t	outton Add	
			EXAMINER SIGNATURE			
Examiner	Signa	ture		Date Considered		

1 See Kind Code of USPTO Patent Documents at year USPTO_GOLY or MEPP 901.64. I Enter office that issued the document, by the low-letter (SWIPO) Standard \$13.3. I See Toughanese patent fourment, he included not deep variet for less price the series represent he serial runbient for patent document. I Kind of document by the appropriate symbols as indicated on the document under WIPO Standard \$11.6 if possible. Tappicant is to place a check mark here if Engine Israques presentation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10787062
Filing Date		2004-02-25
First Named Inventor	Kazur	nori YASUDA et al.
Art Unit		3738
Examiner Name Miller		Cheryl
Attorney Docket Number		81880.0115

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information displacate statement. Con 27 CED 1 07(a)/1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	of the agreeter.								
	Signature	/ljm/	Date (YYYY-MM-DD)	2007-09-21					
	Name/Print	Lawrence J. McClure	Registration Number	44228					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.